Clinical trial
A Randomized, Prospective, Double-Blinded, Placebo-Controlled (Sham-Controlled) Study to Evaluate the Safety and Effectiveness of the Adacolumn Apheresis System for the Treatment of Moderate to Severe Ulcerative Colitis
NCT00102193 is registered in ClinicalTrials.gov with Otsuka America Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Prospective, Double-Blinded, Placebo-Controlled (Sham-Controlled) Study to Evaluate the Safety and Effectiveness of the Adacolumn Apheresis System for the Treatment of Moderate to Severe Ulcerative Colitis
- Lead sponsor
- Otsuka America Pharmaceutical
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 31, 2004
- Completion date
- July 31, 2006
- Enrollment
- 168
- Sites
- 37
Conditions
As the registry lists them; a condition with its own page is linked.
ulcerative colitis